While combination antiretroviral treatment has made HIV a treatable condition, eradication of the infection has not yet been achieved. Treatment needs to be administered as a prolonged, possibly lifelong treatment. Long-term toxicity, difficulty in adhering to complex regimes, possible pharmacokinetics problems, and intrinsically limited potency are all factors favouring the selection of drug-resistant viral strains. The development of drug resistance is now a major cause for treatment failure.
EuResist aims to:
For further information, please visit:
http://www.euresist.org
Project co-ordinator:
Informa S.r.l. (IT)
Partners:
Timetable: from 01/06 to 06/08
Total cost: 2.973.355
EC funding: 2.143.000
Instrument: STREP
Project Identifier: IST-2004-027173
Microsoft in Healthcare and Life Sciences
Company Profiles:
Agfa HealthCare |
Carestream Health |
Cetrea |
CompuGroup Medical |
CSC |
CSW Group Ltd |
dbMotion |
Dell Healthcare and Life Sciences |
EMIS |
empirica |
First DataBank |
GE Healthcare |
IBM Healthcare |
Initiate Systems |
InterComponentWare AG (ICW) |
Intel in Healthcare |
InterSystems Corporation |
iPLATO Healthcare |
iSOFT |
Map of Medicine |
Oracle Healthcare Solutions |
Orion Health |
Philips Healthcare |
Picis |
SAP for Healthcare |
Siemens Healthcare |
System C Healthcare |
Telehealth Solutions |
Tieto |
Transinsight |
Toumaz |
Tunstall | ...